COPARIME: Pilot Study of a Target Detection of Malignant Melanoma
- Conditions
- Patients at Risk for Melanoma
- Registration Number
- NCT01610531
- Lead Sponsor
- Nantes University Hospital
- Brief Summary
Melanoma is nowadays an important public health problem because its growing incidence. Mass screening for melanoma is not recommended worldwide because of its low cost-effectiveness. Nevertheless targeted screening for patients at high risk for melanoma is promoted. This study is designed to assess the effectiveness and the acceptability of a melanoma targeted screening of melanoma, to estimate the risk function to develop a melanoma among patients at high risk according to the SAMScore and to estimate the ratio cost/ efficacy of the melanoma targeted screening. A cohort of 7700 patients is carried out in 2 departments covered by a registry of cancers. The recruitment had began in April 2011. Patients assessed at high risk according to the SAMScore were proposed a skin examination by their GP every year.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4118
- patients more than 18 years old,
- consulting their GP,
- assessed at risk for melanoma according to the SAMScore
- signed the consent.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Prevalence ratios between those of the COPARIME cohort and those of the general population. 5 years Number of melanomas detected / Number of patients at high risk of melanoma defined by our selection tool.
- Secondary Outcome Measures
Name Time Method Probability to develop a melanoma at one year. 1 years Cost ratio for a screened melanoma. 5 years
Trial Locations
- Locations (1)
University Hospital
🇫🇷Nantes, France